Wegovy (semaglutide) is not just a tool for weight reduction. Recent clinical evidence has shown that it offers significant protection for the cardiovascular system, particularly for those at higher risk of heart-related issues.
Use this guide to understand:
How Wegovy reduces the risk of serious heart events.
Its impact on obesity-related heart failure.
Why it is a landmark treatment for heart health.
Reducing cardiovascular risk
Clinical data has demonstrated that Wegovy can reduce the risk of heart attack, stroke, or cardiovascular death by approximately 20%. These benefits were seen in adults with overweight or obesity who already had established heart disease, even if they did not have diabetes.
Wegovy is thought to protect the heart through two main pathways:
Sustained weight loss: Supporting a healthy, lower body weight reduces the overall strain on the heart and blood vessels.
Direct heart function: Emerging evidence suggests the medication works directly to improve how the heart functions biologically.
Improving heart failure symptoms
For individuals living with obesity-related heart failure, Wegovy has been shown to improve daily symptoms and increase exercise capacity. This means patients may find it easier to stay active and experience less shortness of breath or fatigue during physical exertion.
A landmark approval
Because of these proven benefits, Wegovy became the first weight-loss medication approved specifically to help prevent heart attacks and strokes in at-risk patients. This makes it a unique option for individuals who are managing both their weight and long-term heart health.
Need further support?
If you still need help after reviewing the information above, additional assistance is available.